Y-mAbs Therapeutics, Inc. (YMAB)

NASDAQ: YMAB · IEX Real-Time Price · USD

11.59

-0.11 (-0.94%)

At close: Jul 19, 2024, 12:00 AM

11.97

+0.38 (3.28%)

Pre-market: Jul 22, 2024, 7:43 AM EDT

Y-mAbs Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2016
Net Income	-21.67	-21.43	-95.57	-55.28	-119.34	-81.03	Upgrade
Depreciation & Amortization	0.71	0.74	0.84	0.78	0.4	0.17	Upgrade
Share-Based Compensation	13	14.45	25.6	19.33	16.14	4.66	Upgrade
Other Operating Activities	-9.63	-20.99	-6.79	-67.4	11.58	2.71	Upgrade
Operating Cash Flow	-17.59	-27.23	-75.92	-102.56	-91.23	-73.5	Upgrade
Capital Expenditures	0	0	0	61.34	-0.18	-1.97	Upgrade
Acquisitions	0	0	0	0	-2.61	0	Upgrade
Other Investing Activities	-	-	-	-0.3	-	-	Upgrade
Investing Cash Flow	0	0	0	61.04	-2.79	-1.97	Upgrade
Share Issuance / Repurchase	0.69	0.1	0.08	108.31	2	134.7	Upgrade
Financing Cash Flow	0.69	0.1	0.08	108.31	2	134.7	Upgrade
Exchange Rate Effect	0.02	0.01	0.04	0.13	-0.49	0.02	Upgrade
Net Cash Flow	-16.88	-27.13	-75.8	66.93	-92.5	59.27	Upgrade
Free Cash Flow	-17.59	-27.23	-75.92	-41.21	-91.41	-75.46	Upgrade
Free Cash Flow Margin	-20.81%	-32.11%	-116.32%	-118.10%	-440.51%	-	Upgrade
Free Cash Flow Per Share	-0.40	-0.62	-1.74	-0.95	-2.28	-2.15	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).